• Evaxion flagged new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, scheduled for presentation at European Hematology Association Congress 2026.
• Results have not yet been presented; poster disclosure set for June 13, 2026, in Stockholm.
• Update is expected to outline functional characterization supporting EVX-04’s development rationale, positioning program for move toward first clinical testing.
• Clinical trial application planned for second half of 2026, marking next major value inflection for asset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120930OMX_____CNEWS_EN_GNW1001181439_en) on May 12, 2026, and is solely responsible for the information contained therein.